Latest News and Press Releases
Want to stay updated on the latest news?
-
WALTHAM, Mass., Oct. 22, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in three upcoming investor conferences....
-
WALTHAM, Mass., Oct. 15, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its third-quarter 2015 financial results on Thursday, October 29, 2015, after the close of the U.S. financial...
-
WALTHAM, Mass., Sept. 24, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the decision of the National Comprehensive Cancer Network...
-
WALTHAM, Mass., Sept. 21, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Martin Huber, M.D., to the position of...
-
Approval Based Upon Four Trials of Patients Receiving Emetogenic Chemotherapy, Including Cisplatin, Carboplatin and Anthracycline/Cyclophosphamide-Based Regimens VARUBI™ to...
-
WALTHAM, Mass., Sept. 1, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in three upcoming investor conferences....
-
U.S. FDA PDUFA action date for oral rolapitant is September 5, 2015 Bioequivalence of IV and oral rolapitant successfully demonstrated Data from Phase 3 NOVA trial of niraparib...
-
WALTHAM, Mass., July 30, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, and Jiangsu Hengrui Medicine Co., Ltd., a fully integrated pharmaceutical...
-
WALTHAM, Mass., July 23, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its second-quarter 2015 financial results on Thursday, August 6, 2015, after the close of the U.S. financial...
-
WALTHAM, Mass., July 13, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Grant C. Bogle to the newly created...